TY - JOUR
T1 - Benefit of azilsartan on blood pressure elevation around rest-to-active phase in spontaneously hypertensive rats
AU - Isegawa, Kengo
AU - Hirooka, Yoshitaka
AU - Kishi, Takuya
AU - Yasukawa, Keiji
AU - Utsumi, Hideo
AU - Sunagawa, Kenji
N1 - Funding Information:
This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (B24390198).
Publisher Copyright:
© 2015 Informa Healthcare USA, Inc.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Abnormal elevation of blood pressure in early morning (rest-to-active phase) is suggested to cause cardiovascular events. We investigated whether azilsartan (AZL), a novel potent angiotensin receptor blocker, suppresses blood pressure elevation from the light-rest to dark-active phase in spontaneously hypertensive rats (SHRs). AZL has a sustained depressor effect around the rest-to-active phase in SHRs to a greater extent than candesartan (CAN), despite their similar depressor effects for over 24 h. AZL did not cause sympathoexcitation. These results suggest that AZL has a more sustained depressor effect than CAN around the rest-to-active phase in SHRs, and might have advantages for early morning hypertension.
AB - Abnormal elevation of blood pressure in early morning (rest-to-active phase) is suggested to cause cardiovascular events. We investigated whether azilsartan (AZL), a novel potent angiotensin receptor blocker, suppresses blood pressure elevation from the light-rest to dark-active phase in spontaneously hypertensive rats (SHRs). AZL has a sustained depressor effect around the rest-to-active phase in SHRs to a greater extent than candesartan (CAN), despite their similar depressor effects for over 24 h. AZL did not cause sympathoexcitation. These results suggest that AZL has a more sustained depressor effect than CAN around the rest-to-active phase in SHRs, and might have advantages for early morning hypertension.
UR - http://www.scopus.com/inward/record.url?scp=84921280146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921280146&partnerID=8YFLogxK
U2 - 10.3109/10641963.2014.897721
DO - 10.3109/10641963.2014.897721
M3 - Article
C2 - 24678965
AN - SCOPUS:84921280146
SN - 1064-1963
VL - 37
SP - 45
EP - 50
JO - Clinical and Experimental Hypertension
JF - Clinical and Experimental Hypertension
IS - 1
ER -